Table 1

Baseline patient demographics and characteristics, by treatment group

1 mg/kg
Q2W
n=16
3 mg/kg
Q2W
n=15
10 mg/kg
Q2W
n=11
3 mg/kg
Q4W
n=6
5 mg/kg
Q4W
n=10
All patients
N=58
Median age, years (range)47 (26–77)61 (25–82)54 (37–82)52 (25–59)56 (23–73)54.5 (23–82)
Sex (male), n (%)7 (43.8)8 (53.3)7 (63.6)4 (66.7)6 (60.0)32 (55.2)
Race, n (%)
 Caucasian10 (62.5)14 (93.3)8 (72.7)4 (66.7)8 (80.0)44 (75.9)
 Black2 (12.5)00002 (3.4)
 Asian3 (18.8)1 (6.7)2 (18.2)2 (33.3)1 (10.0)9 (15.5)
 Unknown1 (6.3)00001 (1.7)
 Other001 (9.1)01 (10.0)2 (3.4)
ECOG PS, n (%)
 08 (50.0)2 (13.3)5 (45.5)3 (50.0)6 (60.0)24 (41.4)
 18 (50.0)13 (86.7)6 (54.5)2 (33.3)4 (40.0)33 (56.9)
 20001 (16.7)01 (1.7)
Primary tumor type, n (%)
 Anal cancer002 (18.2)002 (3.4)
 ATC01 (6.7)0001 (1.17)
 Breast cancer01 (6.7)1 (9.1)01 (10.0)3 (5.2)
  TNBC01 (6.7)0001 (6.7)
 Carcinoid01 (6.7)0001 (1.7)
 Cholangiocarcinoma01 (6.7)1 (9.1)002 (3.4)
 Esophageal cancer001 (9.1)1 (16.7)02 (3.4)
 H&N cancer1 (6.3)1 (6.7)001 (10.0)3 (5.2)
 HCC2 (12.5)00002 (3.4)
 Melanoma, cutaneous001 (9.1)001 (1.7)
 Merkel cell carcinoma001 (9.1)01 (10.0)2 (3.4)
 Mesothelioma01 (6.7)0001 (6.7)
 mRCC2 (12.5)1 (6.7)1 (9.1)1 (16.7)1 (10.0)6 (10.3)
 Neuroendocrine carcinoma2 (12.5)00002 (3.4)
 NSCLC, adenocarcinoma01 (6.7)0001 (1.7)
 Ovarian cancer1 (6.3)001 (16.7)02 (3.4)
 Prostate cancer1 (6.3)00001 (1.7)
 Sarcoma4 (25.0)4 (26.7)2 (18.2)2 (33.3)4 (40.0)16 (27.6)
  Liposarcoma2 (12.5)1 (6.7)0003 (5.2)
 SCLC01 (6.7)1 (9.1)002 (3.4)
 Solid tumor00001 (10.0)1 (1.7)
 Squamous cell carcinoma of skin00001 (10.0)1 (1.7)
 Testicular cancer1 (6.3)00001 (1.7)
 Urothelial carcinoma01 (6.7)01 (6.7)02 (3.4)
 Other2 (12.5)1 (6.7)0003 (5.2)
Prior treatment regimens, n (%)
 001 (6.7)1 (9.1)02 (20.0)4 (6.9)
 14 (25.0)2 (13.3)1 (9.1)007 (12.1)
 22 (12.5)7 (46.7)2 (18.2)1 (16.7)2 (20.0)14 (24.1)
 ≥310 (62.5)5 (33.3)7 (63.6)5 (83.3)6 (60.0)33 (56.9)
Prior radiotherapy, n (%)
 Yes7 (43.8)8 (53.3)8 (72.7)2 (33.3)6 (60.0)31 (53.4)
 No9 (56.3)7 (46.7)3 (27.3)4 (66.7)4 (40.0)27 (46.6)
PD-L1+ cells, n (%)
 <1%11 (68.8)9 (60.0)7 (63.6)5 (83.3)7 (70.0)39 (67.2)
 1–<5%1 (6.3)3 (20.0)0004 (6.9)
 5–<50%2 (12.5)2 (13.3)2 (18.2)02 (20.0)8 (13.8)
 ≥50%1 (6.3)1 (6.7)1 (9.1)01 (10.0)4 (6.9)
 Missing1 (6.3)01 (9.1)1 (16.7)03 (5.2)
  • ATC, anaplastic thyroid cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; HCC, hepatocellular carcinoma; H&N, head and neck cancer; mRCC, metastatic renal cell carcinoma; NSCLC, non-small cell lung cancer; PD-L1, programed death ligand 1; Q2W, once every 2 weeks; Q4W, once every 4 weeks; SCLC, small cell lung cancer; TNBC, triple-negative breast cancer.